GlobalData on MSN4d
Palatin concludes Phase II trial of combination therapy for obesityPalatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...
Displacement of radio-iodinated ACTH by cold ACTH, but not by other unrelated peptides, was shown, 5 as was the dependence ... Expression studies with cloned melanocortin receptors have confirmed ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback